EVALUATION OF SIV EXPRESSING IGIF

表达 IGIF 的 SIV 的评估

• 批准号: 7562418
• 负责人: Luis David Giavedoni
• 金额: $ 4.85万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562418
• 关键词: Attenuated; Attenuated Live Virus Vaccine; B-Lymphocytes; Computer Retrieval of Information on Scientific Projects Database; Effector Cell; Evaluation; Funding; Grant; IL18 gene; Immune response; Immune system; Infection; Infection prevention; Institution; Interleukin-18; Life; Link; Macaca mulatta; Natural Killer Cells; Recombinants; Research; Research Personnel; Resources; SIV; SIV Vaccines; Source; United States National Institutes of Health; Viral; Virulence; in vivo

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Interleukin-18 (IL-18, interferon-gamma inducing factor [IGIF]) represents a functional link between effector cells of the innate (phagocytic and NK cells) and adaptive (T- and B-lymphocytes) immune systems. Expression of IL-18 by a live-attenuated SIV vaccine may reduce viral virulence and induce a Type-1 immune response that may prevent infection with pathogenic SIV. The objective of this study was to evaluate the in vivo effects of the infection of rhesus macaques with a recombinant SIV?nef that expresses the rhesus IL18 gene and its potential use as a live-attenuated vaccine (SIVIL18).

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 白介素18(IL-18，干扰素-γ诱导因子[IGIF])是天然免疫系统(吞噬细胞和NK细胞)和获得性免疫系统(T和B淋巴细胞)的效应细胞之间的功能联系。用SIV减毒活疫苗表达IL-18可以降低病毒毒力，并诱导1型免疫反应，从而防止感染致病性SIV。本研究旨在评价表达IL-18基因的重组SIV-NEF对恒河猴的体内感染效果及其作为减毒活疫苗(SIVIL-18)的应用前景。